Perla Rocío Colunga-Pedraza

No ORCID on file · 1 paper in corpus
other 2017
Clinical lymphoma, myeloma & leukemia ·doi:10.1016/j.clml.2017.11.007

BACKGROUND: Allogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic…